Sign in
CompletedPhase 3

A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD

Key facts

Who runs it
Lipocine Inc.
Where
Anahiem, Atlanta, Beaumont, Canoga Park, Decatur, Houston, Idaho Falls, Kansas City, Las Vegas, League City, Media, Miami, Miami Gardens, Monroe, New Orleans, Provo, and Savannah, United StatesSee the 18 sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
90 people enrolled
Started
16 Jun 2025
Ended
17 Feb 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • LPCN 1154A
  • Placebo
Record updated
24 February 2026

Who can take part

Age
15 years to 45 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Are female between 15 and 45 years of age, inclusive
  • Have had a depressive episode that began no earlier than third trimester and later than the first 4 week following delivery
  • Are < 12 months postpartum at Screening
  • Hamilton Depression Rating Scale (HAM-D) 17-item score indicative of severe depression

Who cannot take part

  • Have a history of bipolar disorder, schizophrenia or schizoaffective disorder
  • Have a history of suicidal behavior within 1 year
  • Have a history of seizure within 6 months of Screening
  • Are currently experiencing active psychosis per Investigator assessment

Where in United States

  • Advanced Research CenterAnahiem, United States
  • Atlanta Behavioral ResearchAtlanta, United States
  • Gadolin ResearchBeaumont, United States
  • Alliance Research InstituteCanoga Park, United States
  • CenExel Research CenterDecatur, United States
  • New Dawn Wellness and Medical CenterHouston, United States
  • Clinical Research PrimeIdaho Falls, United States
  • Cypress Medical Research Center, LLCKansas City, United States
  • Oasis Clinical ResearchLas Vegas, United States
  • Maximos Ob/GynLeague City, United States
  • Suburban Research AssociatesMedia, United States
  • D&H National Research CentersMiami, United States
  • MedOne Clinical Research LLCMiami, United States
  • Meridian International ResearchMiami Gardens, United States
  • Monroe Biomedical ResearchMonroe, United States
  • Best Clinical TrialsNew Orleans, United States
  • Populace ResearchProvo, United States
  • CenExel Research CenterSavannah, United States

About the trial

What the trial wants to find out

The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine:

Read full original descriptionShow less

* If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause * If LPCN 1154A reduces anxiety symptoms in subjects with severe PPD

The 2 groups in the trial

  • LPCN 1154A TabletsTreatment being tested

    LPCN 1154A

    Treatment: LPCN 1154A

  • Placebo TabletsPlacebo, for comparison

    Treatment: Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Blinded, Placebo-Controlled Study to Evaluate the Saftey and Efficacy of Oral LPCN 1154A in Women With Postpartum Depression
Record updated
24 February 2026